

Allan Kimaina¹, Jonathan Dick MD^{2,3,4}, Allison DeLong^{1,4}, Rami Kantor MD^{1,4,5,6}, Hogan Joseph ScD^{1,4,5}

Brown University, Providence, RI, USA¹; Center for Biomedical Informatics, Regenstrief Institute, Indianapolis, IN, USA²; Indiana University School of Medicine, Indianapolis, IN, USA³; AMPATH Consortium, Eldoret, Kenya⁴; CFAR Core, Providence, RI, USA⁵, The Miriam Hospital, Lifespan, Providence, RI USA⁵.



Background

Viral Failure

Objective

Methods


Results

Threshold

Calibration

Inference

Conclusion



- As a measure to achieve the last 90% of the ambitious UNAIDS 90-90-90 targets, WHO guidelines recommend that, where possible, HIV viral load suppression to be assessed six months immediately after starting ART and annually or semi-annually thereafter.
- However, a major deficiency of the current model is in its inability to detect virologic failures early enough.












Allan Kimaina¹, Jonathan Dick MD^{2,3,4}, Allison DeLong^{1,4}, Rami Kantor MD^{1,4,5,6}, Hogan Joseph ScD^{1,4,5}





Background

Viral Failure

Objective

Methods


Results


Threshold

Calibration

Inference

Conclusion






- Delays in efforts to detect and address potential virologic failures ultimately lead to **adverse clinical trajectories** such as patient-level treatment failures, immunological failures as well as clinical failures.
- Not only does virologic failure increases morbidity for the patient, but also creates a significant **public** health risk for HIV transmission





Allan Kimaina¹, Jonathan Dick MD^{2,3,4}, Allison DeLong^{1,4}, Rami Kantor MD^{1,4,5,6}, Hogan Joseph ScD^{1,4,5}





Background

Viral Failure

Objective


Methods

Results

Threshold

Calibration

Inference



• To achieve most of the benefits of the current WHO HIV model, timely detection of potential virologic failure is critical in administering essential **patient-centered interventions**. As such, this study aims to disseminate some techniques that can potentially be utilized in HIV clinical settings with rich, structured EHR to **proactively** anticipate and mitigate potential **risk of virologic failure** before they manifest.







Conclusion

Harnessing the Power of Machine Learning Methods for Enhancing HIV Care and Treatment Within Resource-Limited Settings

Allan Kimaina¹, Jonathan Dick MD^{2,3,4}, Allison DeLong^{1,4}, Rami Kantor MD^{1,4,5,6}, Hogan Joseph ScD^{1,4,5}



Brown University, Providence, RI, USA¹; Center for Biomedical Informatics, Regenstrief Institute, Indianapolis, IN, USA²; Indiana University School of Medicine, Indianapolis, IN, USA³; AMPATH Consortium, Eldoret Kenya⁴: CFAR Core, Providence, RI, USA⁵ The Mirjam Hospital Lifespan, Providence, RI, USA⁵

Global Health Initiative Consortium, Eldoret, Kenya ⁴ ; CFAR Core, Providence, RI, USA ⁵ , The Miriam Hospital, Lifespan, Providence, RI USA ⁵ .							
Background	Over 256 million clinical Obs for over 90,000 patients de-identified		Data visualization & descriptive statistics		Hyperparameter tuning using cross-validation		
Viral Failure	Data I	ngestion Data Prep	Data Exp	loration Feature C		Training Model Evaluati	ion
Objective	MEDICAL RECORD 3131EM	Over 100 predict 30,000 patients	tors for over	50 clinically-releva	ant covariates	Model discriminatory anal calibration	
Methods	Study Design: A retrospective observational study was conducted by analyzing and creating <i>virologic failure risk prediction model</i> using vast amounts of clinical & non-clinical profile collected between <i>January 2014</i> and <i>March 2018</i> .						
Results	Population Setting: The de-identified training & validation dataset was extracted from AMPATH's EHR serving over 90,000 HIV patients in Kenya. All patients younger than 18 years old or patients with less than 2 viral load tests were excluded from the dataset, thereby decreasing the sample size to 30,039 patients. Risk Predictive Modeling: A comparative analysis was conducted by training a series of ML models using 50						
Threshold							
Calibration	clinically-relevant covariates that were handpicked and curated by domain experts. The risk model can be expressed as: $E(Y_t V_{t-1}) \text{ or } Pr(Y_t = 1 V_{t-1}) = \pi \qquad Y \sim Bern(\pi)$ where V_{t-1} denotes baseline covariates before time point t , Y_t is a binary outcome for virologic failure while t is the time						
Inference	point relative to viral load count me						

Evaluation Criteria: Internal validation (sensitivity, AUC and specificity), as well as calibration & discriminatory,

were used to assess the discriminatory ability of each model in distinguishing between low-risk and high-risk patients.



is ampath

Allan Kimaina¹, Jonathan Dick MD^{2,3,4}, Allison DeLong^{1,4}, Rami Kantor MD^{1,4,5,6}, Hogan Joseph ScD^{1,4,5}

Brown University, Providence, RI, USA1; Center for Biomedical Informatics, Regenstrief Institute, Indianapolis, IN, USA2; Indiana University School of Medicine, Indianapolis, IN, USA3; AMPATH Consortium, Eldoret, Kenya⁴; CFAR Core, Providence, RI, USA⁵, The Miriam Hospital, Lifespan, Providence, RI USA⁶,

NAMBARI



Viral Failure

Objective


Methods

Results

Threshold

Calibration

Inference



Holding the cutoff at .5, the 10-fold cross-validated performance summary for predicting the first risk of virologic failure at baseline using only baseline covariates is illustrated above (**newly enrolled patients**).



Conclusion



WampathWampath

Wampath

Allan Kimaina¹, Jonathan Dick MD^{2,3,4}, Allison DeLong^{1,4}, Rami Kantor MD^{1,4,5,6}, Hogan Joseph ScD^{1,4,5}

Brown University, Providence, RI, USA¹; Center for Biomedical Informatics, Regenstrief Institute, Indianapolis, IN, USA²; Indiana University School of Medicine, Indianapolis, IN, USA³; AMPATH Consortium, Eldoret, Kenya⁴; CFAR Core, Providence, RI, USA⁵. The Miriam Hospital, Lifespan, Providence, RI USA⁶.

Background

Viral Failure

Objective


Methods

Results

Threshold

Calibration

Inference




Holding the cutoff at .5, the **10-fold cross-validated** performance summary for predicting the second risk of virologic failure using baseline covariates & Y1 is illustrated above (**currently enrolled patients**).







Allan Kimaina¹, Jonathan Dick MD^{2,3,4}, Allison DeLong^{1,4}, Rami Kantor MD^{1,4,5,6}, Hogan Joseph ScD^{1,4,5}







Viral Failure

Objective

Methods


Results

Threshold

Calibration

Inference

Conclusion




The panel above illustrates the tradeoff faced upon selecting a reasonable probability threshold other than .5. Using a cutoff value of .3, gave better performance in most classifiers. Adjusting the cutoff to .25 boosted the sensitivity of some methods like XGBoost, GBM, and BART to .92, .87, and .90 respectively.





Allan Kimaina¹, Jonathan Dick MD^{2,3,4}, Allison DeLong^{1,4}, Rami Kantor MD^{1,4,5,6}, Hogan Joseph ScD^{1,4,5}







Viral Failure

Objective

Methods


Results

Threshold

Calibration

Inference

Conclusion




Ensemble methods such as XGBoost and GBM were naturally well calibrated while some were not. RF, for instance, exhibited "optimism," i.e., its predictions for Pr(Y_2=1)>0.5 were extremely high relative to the observed event rate; while others like KNN, OLS, SVM, PLS were unrealistically underconfident.





Allan Kimaina¹, Jonathan Dick MD^{2,3,4}, Allison DeLong^{1,4}, Rami Kantor MD^{1,4,5,6}, Hogan Joseph ScD^{1,4,5}





Background

Viral Failure

Objective

Methods


Results

Threshold

Calibration

Inference

Conclusion




Previous virologic failure turned out to be the most important predictor. Other notable important predictors consisted of BMI, the proportion of days on ARVs, baseline ARV Line, number of clinical encounters, gender, age, referral order status, health cover status and TB-related variables e.g symptoms.





Allan Kimaina¹, Jonathan Dick MD^{2,3,4}, Allison DeLong^{1,4}, Rami Kantor MD^{1,4,5,6}, Hogan Joseph ScD^{1,4,5}





Background

Viral Failure

Objective

Methods


Results

Threshold

Calibration

Inference

Conclusion



As a step towards personalized healthcare in HIV care, prospective virologic assessments can be utilized in clinical settings with rich EHR data to potentially anticipate and mitigate risk of virologic failure early enough before adverse clinical trajectories manifest. Thus, as a preventative strategy, high-risk patients identified using accurate & well-calibrated risk predictive model will benefit from targeted holistic intervention such as:

- Intensified adherence counseling
- Rigorous nutrition monitoring
- Timely psychosocial counseling
- Early ordering of lab orders such as viral load tests
- Appropriate next-line therapy switching
- Enhanced drug toxicity/drug resistance/adverse drug-drug interaction monitoring